Simon Stertzer Acquires 70,200 Shares of BioCardia (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer bought 70,200 shares of the stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of $0.92 per share, for a total transaction of $64,584.00. Following the completion of the acquisition, the director owned 127,338 shares in the company, valued at approximately $117,150.96. The trade was a 122.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BioCardia Price Performance

Shares of NASDAQ:BCDA traded up $0.06 during midday trading on Wednesday, hitting $1.06. The company had a trading volume of 489,451 shares, compared to its average volume of 1,516,771. The business’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.18. The stock has a market cap of $12.06 million, a price-to-earnings ratio of -1.16 and a beta of 0.51. BioCardia, Inc. has a twelve month low of $0.78 and a twelve month high of $2.45.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). As a group, sell-side analysts forecast that BioCardia, Inc. will post -0.76 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research report on Tuesday, June 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $25.00.

Institutional Investors Weigh In On BioCardia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers purchased a new stake in BioCardia in the second quarter valued at $40,000. Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the period. Finally, DRW Securities LLC purchased a new position in shares of BioCardia during the 4th quarter worth $72,000. Institutional investors and hedge funds own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.